FDA issued 8 Warning Letters to Companies because of Missing Establishment Registration
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Within 5 months, the FDA has issued 8 Warning Letters to companies who failed to comply with the obligation to register production establishments. These companies are mainly located in Asia but also in France and Columbia.
Under section 510(i)(1) of the Act 21 U.S.C. § 360(i)(1), companies are required to submit registration information annually by electronic means about the manufacture of medicinal products that are imported or offered for import into the United States. Part 207 of Title 21 of the CFR lays down the requirements regarding registration and the necessary updates and changes.
Registration by electronic means must be made on the following page: FDA Electronic Drug Registration and Listing Page.
The Warning Letters are listed below:
25 January 2012: China Zhejiang Xianju Chemical Pharmaceutical Factory
28 February 2012: India Pan Drugs Limited
28 Feburary 2012: China Chinese Peptide Company
15 March 2012: France Orlane S.A.
26 March 2012: Korea Korea Pharma Company Ltd
5 April 2012: Hong Kong Peking Medicine Manufactory
15 May 2012: Columbia C.I. Farmacapsulas S.A.
Related GMP News
21.10.2026Switzerland: GMP Compliance by Foreign Manufacturers
14.10.2026EU Pharma Package: Council Adopts New Rules
14.10.2026ICH Publishes New Training Material for Quality Guidelines
14.10.2026WHO issues Draft Guidance on Quality Risk Management
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA